Adoptive transfer of autologous T cells followed by vaccination with MAGE-A4-derived peptides after chemotherapy for MAGE-A4-expressing advanced cancer patients - Adoptive T cell transfer therapy with MAGE-A4 peptide vaccination

Department of Immuno-gene Therapy, Mie University Graduate School of Medicine0 sites9 target enrollmentMarch 4, 2008

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Head and neck cancer, Ovarian cancer, Esophageal cancer, Multiple myeloma
Sponsor: Department of Immuno-gene Therapy, Mie University Graduate School of Medicine
Enrollment: 9
Status: Completed
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

March 4, 2008

End Date

March 1, 2010

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Department of Immuno-gene Therapy, Mie University Graduate School of Medicine

•1\)Positive either for HIV, HBV, HCV or HTLV\-1 2\)Allergic for agents used in this study, or prior allergic reactions requiring treatments 3\)Notable fluid retention, including pleural effusion, ascites, or pericardial effusion. 4\)Brain metastasis manifesting clinical signs and symptoms 5\)Active infection 6\)Unstable angina pectoris, history of myocardial infarction less than six months prior, or serious arrhythmia requiring treatments. 7\)Interstitional pneumonia or pulmonary fibrosis 8\)History of widespread bone marrow irradiation. 9\)Paralysis or obstruction of gastrointestinal tracts. 10\)Active double cancers occurring within five years, except lesions of "carcinoma in situ" or intramucosal location which are curatively resectable. 11\)Uncontrolled diabetes mellitus 12\)Women who are pregnant, milking , possibly pregnant, or refuse anticonception. 13\)Judged as inappropriate for the study entry by the principle investigator or physicians responsible for the study.